Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected?

@article{Christensen2000BioavailabilityAP,
  title={Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected?},
  author={Hanne Rolighed Christensen and Kristian Antonsen and K{\aa}re Simonsen and A L Lindekaer and Jan Bonde and Helle Riis Angelo and Jens Peter Konnerup Kampmann},
  journal={Pharmacology & toxicology},
  year={2000},
  volume={86 4},
  pages={178-82}
}
Isradipine is a calcium channel-blocking agent of the dihydropyridine type, used in the treatment of hypertension. A terminal half-life of 8-9 hr has been reported, in several pharmacokinetic studies after oral administration of isradipine. In a yet unpublished study a much shorter half-life was observed, and the present trial was therefore conducted in… CONTINUE READING